Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Filing date Form Description View
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
SC 13G/A

An amendment to the SC 13G filing

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Pagination